

- cancer. De Manzoni G, Roviello F, Siquini W, editors. Foreword by Keiichi Maruyama. Italia: Springer-Verlag; 2012.
14. Mullen JT, Kwak EL, Hong TS. What's the best way to treat GE junction tumors? Approach like Gastric Cancer. *Ann Surg Oncol* 2016;23:3780-5.
 15. Hashimoto T, Kurokawa Y, Mori M, et al. Surgical Treatment of Gastroesophageal Junction Cancer. *J Gastric Cancer* 2018 Sep;18(3):209-217.
 16. Blank S, Schmidt T, Heger P, et al. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEGII): thoracoabdominal or abdominal approach? *Gastric Cancer* 2018;21:303-14.
 17. De Manzoni G, Zanoni A, Pedrazzani C. Surgical treatment of Gastric Cancer Infiltrating the Esophago-gastric Junction. In: *Surgery in the multimodal management of gastric cancer*. De Manzoni G, Roviello F, Siquini W, editors. Foreword by Keiichi Maruyama. Italia: Springer-Verlag; 2012.
 18. Carboni F, Lepiane P, Santoro R, et al. Extended multiorgan resection for T4 gastric carcinoma: 25 years experience. *J Surg Oncol* 2005;90:95-100.
 19. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg* 2006;93:559-63.
 20. Bonekamp JJ, Hermans J, Sasako M, et al. Extended lymph node dissection for gastric cancer. *N Engl J Med* 1999;340:908-14.
 21. Wakatsuki K, Takayama T, Ueno M, et al. Characteristics of gastric cancer with esophageal invasion and aspects of surgical treatment. *World J Surg* 2009;33(7):1446-53.
 22. Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus Omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomized controlled trial. *Lancet Gastroenterol Hepatol* 2018;3(7):460-8.
 23. Dhar DK, Kubota H, Tachibana M, et al. Prognosis of T4 gastric carcinoma patients: an appraisal of aggressive surgical treatment. *J Surg Oncol* 2001;76:278-82.
 24. Suárez García A, Cuberes Monserrat R. Tumores Gástricos Malignos. En: Parrilla Paricio P, Landa García I, editores. *Cirugía de la AEC. 2.ª edición*. Madrid: Editorial Médica Panamericana; 2010.
 25. Smith BR, Stabile BE. Aggressive D2 Lymphadenectomy is required for accurate pathologic staging of gastric adenocarcinoma. *Am Surgeon* 2006;72:849-52.
 26. Woo Y, Goldner B, Ituarte P, et al. Lymphadenectomy with optimum of 29 Lymph nodes retrieved associated with improved survival in advanced gastric cancer: a 25.000 patient international study. *J Am Coll Surg* 2017;224(4):546-55.
 27. Verlato G, Roviello F, Marchet A, et al. Indexes of surgical quality in gastric cancer surgery: experience of an Italian network. *An Surg Oncol* 2009;16:594-602.
 28. Iwahashi M, Nakamori M, Nakamura M, et al. Evaluation of double tract reconstruction after total gastrectomy in patients with gastric cancer prospective randomized controlled trial. *World J Surg* 2009;33(9):1882-8.
 29. Pedrazzani C, Marelli D, Rampone B, et al. Postoperative complications and functional results after subtotal gastrectomy with Billroth II reconstruction for primary gastric cancer. *Dig Dis Sci* 2007;52:1757-63.
 30. Gil-Rendo A, Hernández-Lizoain JL. Risk factors related to operative morbidity in patients undergoing gastrectomy for gastric cancer. *Clin Tncol* 2006;8:354-61.
 31. Ikeguchi M. Postoperative morbidity and mortality after gastrectomy for gastric carcinoma. *Hepatogastroenterology* 2001;48:1517-20.
 32. Van Putten M, Nellen SD, Lemmens VEPP, et al. Overall survival before and after centralization of gastric cancer surgery in the Netherlands. *Br J Surg* 2011;105(13):1807-15.
 33. Ozer I, Bostanci EB, Orug T, et al. Surgical outcomes and survival after multiorgan re-section for locally advanced gastric cancer. *Am J Surg* 2009;198:25-30.
 34. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five year survival rates in a multicenter randomized Italian trial. *Italian Gastrointestinal tumor study group*. *Ann Surg* 1999;230:170-8.
 35. Rodella L, Laterza E, de Manzoni G, et al. Endoscopic clipping of anastomotic leakages in esophagogastric surgery. *Endoscopy* 1998;30:453-6.
 36. Salminen P, Gullichsen R, Laine S. Use of self-expandable metal stents for the treatment of esophageal perforations and anastomotic leaks. *Epub Surg Endosc* 2009;23:1526-30.
 37. Shubert D, Scheidbach H, Kuhn R, et al. Endoscopic treatment of thoracic esophageal anastomotic leaks by using silicone-covered, self expanding polyester stents. *Gastrointest Endosc* 2005;61:891-6.
 38. Tarazi R, Coutsofides T, Steiger E, et al. Gastric and duodenal cutaneous fistulas. *World J Surg* 1983;7:463-73.
 39. Garden O, Kikes E, Carter D. Surgical and nutritional management of postoperative duodenal fistula. *Dig Dis Sci* 1988;33:30-5.
 40. Bassi C, Dervenis C, Buturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery* 2005;138:8-13.
 41. Fischer A, Baier P. Endoscopic management of pancreatic fistulas secondary to intraabdominal operation. *Surg Endosc* 2004;18:706-8.
 42. Yol S, Bostanci E, Ozogul Y, et al. A rare complication of D3 dissection for gastric carcinoma: Chyloperitoneum. *Gastric Cancer* 2005;8:35-8.
 43. Fairweather M, Santos A, Ravindra K, et al. Chylous ascites. *Am Surg* 2010;76:442-4.
 44. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol* 2006;24:2903-9.
 45. Bang YJ, Van Cutsem E, Feyereislova, et al.; ToGA. Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;16:376(9749):1302.
 46. Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. *J Gastrointest Oncol* 2011;2:77-84.
 47. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma. Review and considerations for future directions. *Ann Surg* 2005;241:27-39.
 48. Okano K, Maeb, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. *Ann Surg* 2002;235:86-91.
 49. Ambiru S, Miyazaki M, Ito H, et al. Benefits and limits of hepatic resection for gastric metastases. *Am J Surg* 2001;181:279-83.
 50. Luo Z, Rong Z, Huang Ch. Surgery strategies for gastric cancer with liver metastasis. *Frontiers in Oncology* 2019;Dec 6:9:1353.
 51. Kerkar SP, Kemp CD, Avital I, et al. Liver resections in metastatic gastric cancer. *HPB* 2002. 12:589-96.
 52. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002;20:1996-2004.
 53. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol* 2008;15(9):2426-32.
 54. Sugarbaker PH. Peritonectomy procedures. *Ann Surg* 1995;221(1):29-42.
 55. Yonemura Y, Bandou E, Kinoshita K, et al. Effective therapy for peritoneal dissemination in gastric cancer. *Surg Oncol Clin N Am* 2003;12(3):635-48.
 56. Glehen O, Schreiber V, Cotte E. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. *Arch Surg* 2004;139(1):20-6.

57. Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality and morbidity. *J Surg Oncol* 2011;104(6):692-8.
58. Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. *Eur J Surg Oncol* 2006;32(6):661-5.
59. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. *J Surg Oncol* 2009;100(4):311-16.
60. Roig-García J, Girmonés-Vilá J, Garsot-Savall E, et al. Gastrectomía por laparoscopia en el cáncer gástrico. Experiencia en una serie de 56 pacientes. *Cir Esp* 2008;83(2):65-70.
61. Tanaka N, Katai H, Saka M. Laparoscopy assisted pylorus preserving gastrectomy: a matched case-control study. *Surg Endosc* 2011;25:114-8.
62. Katai H, Sasako M, Fukuda K, et al. Safety and feasibility of laparoscopy assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). *Gastric Cancer* 2010; 13:238-44.
63. Katai H, Mizusawa J, Morita S, et al. Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912). *J Clin Oncol* 2019;37(Suppl 15):4020.
64. Kim HH, Han SY, Kim MC, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with Stage I gastric cancer: the KLASS0-01 randomized clinical trial. *JAMA Oncol* 2019;5:506-13.
65. Haverkamp L, Brenkman J, Seesing M, et al. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). *BMC Cancer* 2015;15(1):556.
66. Straatman J, van der Wielen N, Cuesta MA, et al. Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH-trial): Study protocol for a randomized controlled trial. *Trials* 2015;16:123.
67. Wang W, Tu Ch, Shao CH, et al. Impact of enhanced recovery after surgery on postoperative rehabilitation, inflammation, and immunity in gastric carcinoma patients: a randomized clinical trial. *Braz J Med Biol Res* 2019;52(5). DOI:10.1590/1414-431X20198265
68. Bruna M, Vorwald P, Ortega S, et al. Rehabilitación multimodal en la cirugía de resección gástrica. *Cir Esp* 2017;95(2):73-82.